JPH11510156A - キノロン類およびその医療上の使用 - Google Patents

キノロン類およびその医療上の使用

Info

Publication number
JPH11510156A
JPH11510156A JP9507375A JP50737597A JPH11510156A JP H11510156 A JPH11510156 A JP H11510156A JP 9507375 A JP9507375 A JP 9507375A JP 50737597 A JP50737597 A JP 50737597A JP H11510156 A JPH11510156 A JP H11510156A
Authority
JP
Japan
Prior art keywords
ethyl
dihydro
pyrido
oxo
pyrrolidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9507375A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11510156A5 (enExample
Inventor
ビーズリー，スティーブン・コリン
モンタナ，ジョン・ゲイリー
ダイク，ヘイゼル・ジョーン
ホーガン，アラン・ファインドレイ
ランシー，カレン・アン
マナラック，デイビッド・トーマス
バックリー，ジョージ・マーティン
マキシー，ロバート・ジェイムズ
ケンドール，ハナ・ジェーン
バクスター，アンドリュー・ダグラス
Original Assignee
カイロサイエンス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515812.7A external-priority patent/GB9515812D0/en
Priority claimed from GBGB9523679.0A external-priority patent/GB9523679D0/en
Priority claimed from GBGB9605865.6A external-priority patent/GB9605865D0/en
Priority claimed from GBGB9611898.9A external-priority patent/GB9611898D0/en
Application filed by カイロサイエンス・リミテッド filed Critical カイロサイエンス・リミテッド
Publication of JPH11510156A publication Critical patent/JPH11510156A/ja
Publication of JPH11510156A5 publication Critical patent/JPH11510156A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP9507375A 1995-08-02 1996-07-31 キノロン類およびその医療上の使用 Ceased JPH11510156A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9515812.7A GB9515812D0 (en) 1995-08-02 1995-08-02 Novel compounds
GBGB9523679.0A GB9523679D0 (en) 1995-11-20 1995-11-20 Novel compounds
GBGB9605865.6A GB9605865D0 (en) 1996-03-20 1996-03-20 Novel compounds
GB9523679.0 1996-06-07
GB9515812.7 1996-06-07
GBGB9611898.9A GB9611898D0 (en) 1996-06-07 1996-06-07 Quinolones and their therapeutic use
GB9605865.6 1996-06-07
GB9611898.9 1996-06-07
PCT/GB1996/001866 WO1997004775A1 (en) 1995-08-02 1996-07-31 Quinolones and their therapeutic use

Publications (2)

Publication Number Publication Date
JPH11510156A true JPH11510156A (ja) 1999-09-07
JPH11510156A5 JPH11510156A5 (enExample) 2004-09-09

Family

ID=27451320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9507375A Ceased JPH11510156A (ja) 1995-08-02 1996-07-31 キノロン類およびその医療上の使用

Country Status (10)

Country Link
US (1) US5753666A (enExample)
EP (1) EP0841927B1 (enExample)
JP (1) JPH11510156A (enExample)
AT (1) ATE258437T1 (enExample)
AU (1) AU695132B2 (enExample)
CA (1) CA2225555A1 (enExample)
DE (1) DE69631423T2 (enExample)
ES (1) ES2211965T3 (enExample)
MX (1) MX9800921A (enExample)
WO (1) WO1997004775A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518722A (ja) * 2001-02-13 2004-06-24 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アシル化１，２，３，４−テトラヒドロナフチルアミンおよび医薬としてのその使用
JP2009507920A (ja) * 2005-09-14 2009-02-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼ阻害剤としての５−オキソ−５，８−ジヒドロ−ピリド−ピリミジン

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605437D0 (en) * 1996-03-15 1996-05-15 Iaf Biochem Int Cytomegalovirus inhibiting compounds
CA2268190A1 (en) * 1997-08-06 1999-02-18 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor
US6331548B1 (en) 1998-01-29 2001-12-18 Suntory Limited 1-cycloalkyl-1,8-naphthyridin-4-one derivative as type IV phosphodiesterase inhibitor
AU4849199A (en) * 1998-07-01 2000-01-24 Celgro Fungal growth inhibitors
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
AU2001243240A1 (en) 2000-03-21 2001-10-15 Pharmacia And Upjohn Company Llc 4-oxo-1,4-dihydro(1,8)naphthyridine-3-carboxamides as antiviral agents
CN1398258A (zh) 2000-03-21 2003-02-19 法玛西雅厄普约翰美国公司 用作抗病毒剂的4－羟基噌啉－3－甲酰胺化合物
HK1054037A1 (zh) 2000-03-21 2003-11-14 法玛西雅厄普约翰美国公司 作为抗病毒剂的4-羟基-1，8-二氮杂萘-3-羧酰胺
SI1265873T1 (en) 2000-03-21 2004-02-29 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
IL155089A0 (en) * 2000-10-12 2003-10-31 Merck & Co Inc Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CA2425625A1 (en) * 2000-10-12 2002-07-18 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
EP1326611B1 (en) * 2000-10-12 2007-06-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
CZ20031910A3 (cs) 2000-12-11 2003-12-17 Tularik Inc. Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
AU2002257459B2 (en) * 2001-05-24 2006-12-14 Merck Frosst Canada Ltd 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
WO2003077850A2 (en) * 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
KR20060041254A (ko) * 2003-07-24 2006-05-11 아스텔라스세이야쿠 가부시키가이샤 퀴놀론 유도체 또는 그의 염
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PT1773816E (pt) * 2004-06-24 2015-04-29 Vertex Pharma Moduladores de transportadores de cassete de ligação de atp
DE102004035203A1 (de) 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituierte Chinolone
DE102005030524A1 (de) 2005-06-30 2007-01-18 Aicuris Gmbh & Co. Kg Substituierte Chinolone II
JP5175207B2 (ja) * 2005-11-10 2013-04-03 ケモセントリックス インコーポレーティッド 置換キノロンおよび使用法
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
RS55940B1 (sr) 2005-12-28 2017-09-29 Vertex Pharma Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
DE102006005861A1 (de) 2006-02-09 2007-08-23 Aicuris Gmbh & Co. Kg Substituierte Chinolone III
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2917413B1 (fr) 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
NZ583878A (en) 2007-09-14 2012-10-26 Vertex Pharma Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
US8415333B2 (en) 2009-02-24 2013-04-09 Respiratorious Ab Bronchodilating diazaheteroaryls
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
EP2800568A4 (en) * 2012-01-06 2015-06-10 Univ South Florida COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
CN107998131B (zh) * 2017-12-27 2019-09-24 湖北工业大学 芳香酯类化合物用于制备抗adv-7病毒药物
CN111646941A (zh) * 2020-07-17 2020-09-11 天津科技大学 一种磺酰胺类衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
FR2564832B1 (fr) * 1984-05-23 1987-05-15 Panmedica Sa Nouveaux n-acyl derives d'amino-acides et leurs esters, leur procede de preparation et medicaments les contenant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
JPH02124871A (ja) * 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518722A (ja) * 2001-02-13 2004-06-24 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アシル化１，２，３，４−テトラヒドロナフチルアミンおよび医薬としてのその使用
JP2009507920A (ja) * 2005-09-14 2009-02-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼ阻害剤としての５−オキソ−５，８−ジヒドロ−ピリド−ピリミジン

Also Published As

Publication number Publication date
CA2225555A1 (en) 1997-02-13
ATE258437T1 (de) 2004-02-15
ES2211965T3 (es) 2004-07-16
EP0841927A1 (en) 1998-05-20
MX9800921A (es) 1998-05-31
WO1997004775A1 (en) 1997-02-13
EP0841927B1 (en) 2004-01-28
US5753666A (en) 1998-05-19
AU6626696A (en) 1997-02-26
DE69631423D1 (de) 2004-03-04
AU695132B2 (en) 1998-08-06
DE69631423T2 (de) 2004-12-02

Similar Documents

Publication Publication Date Title
JPH11510156A (ja) キノロン類およびその医療上の使用
JPH11513021A (ja) キノロン類およびその医療上の使用
US5728712A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US5919789A (en) Xanthines and their therapeutic use
US6162830A (en) Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
EP0946541B1 (en) Quinolines and their therapeutic use
AU710825B2 (en) Quinolones and their therapeutic use
JP2000505451A (ja) キノロン類およびこれらの治療的使用
CZ296163B6 (cs) Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
JP2000510866A (ja) Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
JP2003517477A (ja) サイトカイン阻害活性を有する置換ピリダジン類
JPH11505241A (ja) キサンチン類およびこれらの治療的使用
HUP9903797A2 (hu) Benzofurán-karboxamidok és -szulfonamidok, alkalmazásuk gyógyszerkészítmények előállítására és ezek a gyógyszerkészítmények
US5792774A (en) Quinolones and their therapeutic use
JP2002504925A (ja) Ｐｄｅ ｉｖおよび／又はｔｎｆインヒビターとしてのキノリン誘導体
KR20010033842A (ko) 티엔에프 및 피디이-ⅳ 억제 활성을 갖는 헤테로시클릭화합물의 엔-옥사이드
JP2002502851A (ja) ベンゾフラン−４−カルボキサミドとその治療的使用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070227

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070904